Sarepta (SRPT) Closer to Approval with Latest Dataset - RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/8/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- Atlassian results seen as 'game changer' for AI kills software worries
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Wedbush Upgrades Sarepta Therapeutic (SRPT) to Outperform; Case Made for Eteplirsen Approval
October 2, 2015 7:45 AM EDTWedbush upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Outperform with a price target of $56 after the company presented data in its NDA for eteplirsen including its 12 boy study Phase II data in the context of matched natural history, dystrophin data from a... More
New Sarepta Therapeutic (SRPT) Data Supports Approval, Oppenheimer Says
October 2, 2015 7:03 AM EDTOppenheimer analyst Christopher Marai reiterated an Outperform rating and $45 price target on Sarepta Therapeutic (NASDAQ: SRPT) following yesterday's WMS update.
Mara commented, "Importantly, an independent re-read of the previous Phase-2b (study-201) %-dystrophin positive fiber data is consistent, showing statistically significant increases in dystrophin at... More
Baird Maintains Bullish View on Sarepta Therapeutic (SRPT) Following WMS Update
October 1, 2015 3:44 PM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $47 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying they remain bullish following World Muscle Society update.
Skorney commented, "Sarepta provided a wealth of new data today that is currently under FDA review. Confirmation of... More
Sarepta Therapeutic (SRPT) PT Lifted to $55 at Needham & Company
October 1, 2015 2:13 PM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and raised his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $55.00 (from $38.00) following data today.
Messer commented, "In a call with investors, Sarepta highlighted new data generated at the request of the FDA... More
Sarepta Therapeutic (SRPT) WMS Data Impresses a Non-Uber Bull
October 1, 2015 1:58 PM EDTCowen analyst Ritu Baral weighed in on Sarepta Therapeutic (NASDAQ: SRPT) following's today's WMS data. The comments are compelling give Baral is not necessarily a bull on the stock with a Market Perform rating.
Baral said the data was stronger than expected and clean as ever. "Surprisingly, 6MWD was stable at 192 weeks," Baral said. "4th biopsy data showed increase in dystrophin production from baseline across all... More
Sarepta Therapeutic (SRPT) Data 'In-Line', Roth Capital Says
October 1, 2015 8:33 AM EDTRoth Capital analyst Debjit Chattopadhyay reiterated a Buy rating and $50 price target on Sarepta Therapeutic (NASDAQ: SRPT) saying today's data was in-line with expectations.
The analyst commented, "Data inline with expectations demonstrating: Significant functional gains (+151m 6MWT benefit) over 36 months vs. appropriate age,... More
Sarepta Therapeutics (SRPT) Announces Statistically Significant Eteplirsen Phase 2b Data in DMD
October 1, 2015 7:03 AM EDTSarepta Therapeutics (NASDAQ: SRPT) announced additional clinical efficacy and safety data from the Companys Phase IIb program of eteplirsen in patients with Duchenne muscular dystrophy (DMD). The data demonstrated that eteplirsen provided a statistically significant advantage of 151 meters in the ability of study participants to walk at three years, compared with external controls. Further, the fourth biopsy data confirmed the mechanism of action of eteplirsen, demonstrating exon skipping in all patients and dystrophin production in nearly all patients. Safety data remained consistent with prior results.
Eteplirsen, Sareptas lead drug... More
